LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2

Oncogene

Volumn 33, Issue 27, 2014, Pages 3571-3582

  Petrilli, A ^a   Copik, A ^a   Posadas, M ^a   Chang, L S ^b,c   Welling, D B ^c   Giovannini, M ^d   Fernandez Valle C ^a  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^b THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d HOUSE RESEARCH INSTITUTE   (United States)

Author keywords

cell cycle; cell proliferation; cytoskeleton dynamics; LIMK; Neurofibromatosis; schwannomas

Indexed keywords

ACTIN; CASPASE; COFILIN; LIM KINASE; LIM KINASE 1; LIM KINASE 2; LIM PROTEIN; MERLIN; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ACOUSTIC NEURINOMA; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL NUCLEUS; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG TARGETING; GENE DELETION; HUMAN; HUMAN CELL; MITOSIS; MOUSE; NEUROFIBROMATOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SCHWANN CELL; WILD TYPE;

ACTIN DEPOLYMERIZING FACTORS; ANIMALS; APOPTOSIS; AURORA KINASE A; CELL PROLIFERATION; CELL SURVIVAL; G2 PHASE CELL CYCLE CHECKPOINTS; GENE SILENCING; HUMANS; LIM KINASES; M PHASE CELL CYCLE CHECKPOINTS; MICE; MITOSIS; MOLECULAR TARGETED THERAPY; NEUROFIBROMATOSIS 2; NEUROFIBROMIN 2; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; SCHWANN CELLS;

EID: 84903881395     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.320     Document Type: Article

References (42)

1. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993; 363: 515-521.
2. Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z et al. Neurofi-bromatosis type 2. Lancet 2009; 373: 1974-1986.
3. Baser ME, De Rienzo A, Altomare D, Balsara BR, Hedrick NM, Gutmann DH et al. Neurofibromatosis 2 and malignant mesothelioma. Neurology 2002; 59: 290-291.
4. Plotkin SR, Stemmer-Rachamimov AO, Barker 2nd FG, Halpin C, Padera TP, Tyrrell A et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009; 361: 358-367.
5. Kalamarides M, Acosta MT, Babovic-Vuksanovic D, Carpen O, Cichowski K, Evans DG et al. Neurofibromatosis 2011: a report of the Children's Tumor Foundation annual meeting. Acta Neuropathol 2012; 123: 369-380.
6. Li W, Cooper J, Karajannis MA, Giancotti FG. Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus. EMBO Rep 2012; 13: 204-215.
7. Stamenkovic I, Yu Q. Merlin, a 'magic' linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival. Curr Protein Pept Sci 2010; 11: 471-484.
8. Pelton PD, Sherman LS, Rizvi TA, Marchionni MA, Wood P, Friedman RA et al. Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human schwannoma cells. Oncogene 1998; 17: 2195-2209.
9. Kissil JL, Johnson KC, Eckman MS, Jacks T. Merlin phosphorylation by p21-acti-vated kinase 2 and effects of phosphorylation on merlin localization. J Biol Chem 2002; 277: 10394-10399.
10. Shaw RJ, Paez JG, Curto M, Yaktine A, Pruitt WM, Saotome I et al. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell 2001; 1: 63-72.
11. Xiao GH, Beeser A, Chernoff J, Testa JR. p21-Activated kinase links Rac/Cdc42 signaling to merlin. J Biol Chem 2002; 277: 883-886.
12. Kissil JL, Wilker EW, Johnson KC, Eckman MS, Yaffe MB, Jacks T. Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell 2003; 12: 841-849.
13. Nakai Y, Zheng Y, MacCollin M, Ratner N. Temporal control of Rac in Schwann cell-axon interaction is disrupted in NF2-mutant schwannoma cells. J Neurosci 2006; 26: 3390-3395.
14. Thaxton C, Lopera J, Bott M, Fernandez-Valle C. Neuregulin and laminin stimulate phosphorylation of the NF2 tumor suppressor in Schwann cells by distinct protein kinase A and p21-activated kinase-dependent pathways. Oncogene 2008; 27: 2705-2715.
15. Yi C, Wilker EW, Yaffe MB, Stemmer-Rachamimov A, Kissil JL. Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2. Cancer Res 2008; 68: 7932-7937.
16. Manetti F. LIM kinases are attractive targets with many macromolecular partners and only a few small molecule regulators. Med Res Rev 2011; 32: 968-998.
17. Yang N, Higuchi O, Ohashi K, Nagata K, Wada A, Kangawa K et al. Cofilin phos-phorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization. Nature 1998; 393: 809-812.
18. Goyal P, Pandey D, Behring A, Siess W. Inhibition of nuclear import of LIMK2 in endothelial cells by protein kinase C-dependent phosphorylation at Ser-283. J Biol Chem 2005; 280: 27569-27577.
19. Scott RW, Olson MF. LIM kinases: function, regulation and association with human disease. J Mol Med (Berl) 2007; 85: 555-568.
20. Yokoo T, Toyoshima H, Miura M, Wang Y, Iida KT, Suzuki H et al. p57Kip2 regulates actin dynamics by binding and translocating LIM-kinase 1 to the nucleus. J Biol Chem 2003; 278: 52919-52923.
21. Amano T, Kaji N, Ohashi K, Mizuno K. Mitosis-specific activation of LIM motif-containing protein kinase and roles of cofilin phosphorylation and depho-sphorylation in mitosis. J Biol Chem 2002; 277: 22093-22102.
22. Kaji N, Muramoto A, Mizuno K. LIM kinase-mediated cofilin phosphorylation during mitosis is required for precise spindle positioning. J Biol Chem 2008; 283: 4983-4992.
23. Sumi T, Hashigasako A, Matsumoto K, Nakamura T. Different activity regulation and subcellular localization of LIMK1 and LIMK2 during cell cycle transition. Exp Cell Res 2006; 312: 1021-1030.
24. Po'uha ST, Shum MS, Goebel A, Bernard O, Kavallaris M. LIM-kinase 2, a regulator of actin dynamics, is involved in mitotic spindle integrity and sensitivity to microtubule-destabilizing drugs. Oncogene 2010; 29: 597-607.
25. Nikonova AS, Astsaturov I, Serebriiskii IG, Dunbrack Jr. RL, Golemis EA. Aurora A kinase (AURKA) in normal and pathological cell division. Cell Mol Life Sci 2013; 70: 661-687.
26. Barr AR, Gergely F. Aurora-A: the maker and breaker of spindle poles. J Cell Sci 2007; 120: 2987-2996.
27. Ritchey L, Ottman R, Roumanos M, Chakrabarti R. A functional cooperativity between Aurora A kinase and LIM kinase1: implication in the mitotic process. Cell Cycle 2012; 11: 296-309.
28. Johnson EO, Chang KH, Ghosh S, Venkatesh C, Giger K, Low PS et al. LIMK2 is a crucial regulator and effector of Aurora-A-kinase-mediated malignancy. J Cell Sci 2012; 125: 1204-1216.
29. Bagheri-Yarmand R, Mazumdar A, Sahin AA, Kumar R. LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system. Int J Cancer 2006; 118: 2703-2710.
30. Horita Y, Ohashi K, Mukai M, Inoue M, Mizuno K. Suppression of the invasive capacity of rat ascites hepatoma cells by knockdown of Slingshot or LIM kinase J Biol Chem 2008; 283: 6013-6021.
31. Okamoto I, Pirker C, Bilban M, Berger W, Losert D, Marosi C et al. Seven novel and stable translocations associated with oncogenic gene expression in malignant melanoma. Neoplasia 2005; 7: 303-311.
32. McConnell BV, Koto K, Gutierrez-Hartmann A. Nuclear and cytoplasmic LIMK1 enhances human breast cancer progression. Mol Cancer 2011; 10: 75.
33. Manetti F. Recent findings confirm LIM domain kinases as emerging target candidates for cancer therapy. Curr Cancer Drug Targets 2012; 12: 543-560.
34. Giovannini M, Robanus-Maandag E, van der Valk M, Niwa-Kawakita M, Abramowski V, Goutebroze L et al. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev 2000; 14: 1617-1630.
35. Ross-Macdonald P, de Silva H, Guo Q, Xiao H, Hung CY, Penhallow B et al. Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors. Mol Cancer Ther 2008; 11: 3490-3498.
36. Hung G, Li X, Faudoa R, Xeu Z, Kluwe L, Rhim JS et al. Establishment and characterization of a schwannoma cell line from a patient with neurofibromatosis 2. Int J Oncol 2002; 20: 475-482.
37. Arber S, Barbayannis FA, Hanser H, Schneider C, Stanyon CA, Bernard O et al. Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase. Nature 1998; 393: 805-809.
38. Bashour AM, Meng JJ, Ip W, MacCollin M, Ratner N. The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human schwannoma cells. Mol Cell Biol 2002; 22: 1150-1157.
39. Sparrow N, Manetti ME, Bott M, Fabianac T, Petrilli A, Bates ML et al. The actin-severing protein cofilin is downstream of neuregulin signaling and is essential for Schwann cell myelination. J Neurosci 2012; 32: 5284-5297.
40. Cote MC, Lavoie JR, Houle F, Poirier A, Rousseau S, Huot J. Regulation of vascular endothelial growth factor-induced endothelial cell migration by LIM kinase 1-mediated phosphorylation of annexin 1. J Biol Chem 2010; 285: 8013-8021.
41. Thaxton C, Bott M, Walker B, Sparrow NA, Lambert S, Fernandez-Valle C. Schwannomin/merlin promotes Schwann cell elongation and influences myelin segment length. Mol Cell Neurosci 2011; 47: 1-9.
42. Iacovelli J, Lopera J, Bott M, Baldwin E, Khaled A, Uddin N et al. Serum and forskolin cooperate to promote G1 progression in Schwann cells by differentially regulating cyclin D1, cyclin E1, and p27Kip expression. Glia 2007; 55: 1638-1647.